Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase

• US 20080159976A1
• Filed: 09/07/2007
• Published: 07/03/2008
• Est. Priority Date: 04/11/2005
• Status: Abandoned Application

• Current Assignee: Horizon Therapeutics USA, Inc. (Amgen Inc.)
• Original Assignee: Horizon Therapeutics USA, Inc. (Amgen Inc.)
• Inventors: Huang, William, Maroli, Allan N., Rehrig, Claudia D., Alton, Michelle A., Waltrip, Royce W., Wright, David Erick, Hartman, Jacob, Mendelovitz, Simona, Horowitz, Zebulun D.
• Application Number:
  US11/899,688
• Publication Number:
  US 20080159976A1
• Time in Patent Office: Days
• US Class Current: 424/78.17
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: C12Y 107/03003 Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Abstract

Disclosed is a method for lowering elevated uric acid levels in a patient having a plasma level of uric acid (pUAc) of more than about 6 mg/dL, the method consisting of administering to said patient an intravenous injections every 2 to 4 weeks of about 8 mg PEG-uricase.

Claims

1. A method for lowering elevated uric acid levels in a patient having a plasma level of uric acid (pUAc) of more than about 6 mg/dL, said method comprising administering to said patient an intravenous injection every 2 to 4 weeks of about 8 mg PEG-uricase.

2. The method of claim 1, wherein said administration causes uric acid levels in said patient to drop below 6 mg/dL.

3. The method of claim 1, wherein said intravenous injections occur every 2 weeks.

4. The method of claim 1, wherein said intravenous injections occur every 4 weeks.

5. The method of claim 1, wherein said patient is suffering from gout.

6. The method of claim 5, wherein said gout is refractory.

7. The method of claim 1, wherein said gout is chronic or tophaceous.

8. The method of claim 1, wherein said PEG-uricase comprises a mammalian uricase amino acid sequence truncated at the amino terminus or the carboxy terminus or both the amino and carboxy termini by about 1-13 amino acids.

9. The method of claim 8, wherein said truncated amino acid sequence further comprises an amino terminal amino acid, wherein the amino terminal amino acid is selected from the group consisting of alanine, glycine, proline, serine and threonine.